Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation

JAMA

Volumn 293, Issue 6, 2005, Pages 699-706

  O'Brien, Cara L ^a   Gage, Brian F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN; XIMELAGATRAN;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER DYSFUNCTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; STATISTICAL ANALYSIS; STROKE; THROMBOSIS PREVENTION;

EID: 13444291221     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.6.699     Document Type: Article

References (75)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370-2375.
2. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart R. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med. 1995;155:469-473.
3. Wolf PA, Abbott RD, Kannel W. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med. 1987;147:1561-1564.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
5. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
6. Buckingham TA, Hatala R. Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol. 2002;25:447-454.
7. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-2692.
8. Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31:822-827.
9. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160:41-46.
10. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004;91:87-94.
11. Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol. 2003;59:35-43.
12. Eriksson UG, Bredberg U, Hoffmann KJ, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2003;31:294-305.
13. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res. 1999;94:187-197.
14. Petersen P, Grind M, Adler J. Ximelagatran versus warfadn for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol. 2003;41:1445-1451.
15. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691-1698.
16. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293:690-698.
17. NDA 21-686, Ximelagatran (H376/95). Available at: http://www.fda.gov/ ohrms/dockets/ac/04/briefing/2004-4069B1_06_FDA-Backgrounder-C-R-MOR.pdf. Accessed December 31, 2004.
18. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
19. US Bureau of the Census. Statistical Abstract of the United States. Washington, DC: US Government Printing Office; 1992.
20. Yuan Z, Bowlin S, Einstadter D, Cebul R, Conners A, Rimm A. Atrial fibrillation as a risk factor for stroke: a retrospective cohort study of hospitalized Medicare beneficiaries. Am J Public Health. 1998;88:395-400.
21. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994;154:1449-1457.
22. Dries D, Exner D, Gersh B, Domanski M, Waclawiw M, Stevenson L. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol. 1998;32:695-703.
23. Wyse DG, Love JC, Yao Q, et al. Atrial fibrillation: a risk factor for increased mortality-an AVID registry analysis. J Interv Card Electrophysiol. 2001;5:267-273.
24. Dennis MS, Burn JPS, Sandercock PAG, Bamford JM, Wade DT, Warlow C. Long-term survival after first-ever stroke: the Oxfordshire community stroke project. Stroke. 1993;24:796-800.
25. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
26. Miniño A, Arias E, Kochanek K, Murphy S, Smith B. Deaths: final data for 2000. Natl Vital Stat Rep. 2002;50:1-119.
27. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441-2448.
28. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? a decision analysis. Stroke. 2003;34:1710-1716.
29. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: validation of risk stratification schemes. Circulation. 2004;110:2287-2292.
30. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet. 1989;1:175-179.
31. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158:1513-1521.
32. Stroke Prevention in Atria(Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
33. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
34. Hellemons BS, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in nonrheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999;319:958-964.
35. The European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
36. Connolly SJ. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-355.
37. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
38. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-1026.
39. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406-1412.
40. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation (SPAF) Study: final results. Circulation. 1991;84:527-539.
41. Gage BF, Yan Y, Milligan PE, et al. Validation of clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation. Am Heart J. In press.
42. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med. 2001;161:1443-1447.
43. Copland M, Walker ID, Tait RC. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med. 2001;161:2125-2128.
44. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156:409-416.
45. Gage BF, Cardinalli AB, Owens D. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-1836.
46. Thomson R, Parkin D, Eccles M, Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet. 2000;355:956-962.
47. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
48. 2003 Drug Topics Red Book. 10th ed. Montvale, NJ: Thomson PDR; 2003.
49. Coaguchek Systems 2003 Medicare Reimbursement Handbook for Health Care Professionals. Indianapolis, Ind: Roche Diagnostics; 2003.
50. Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ. 2003;12:1049-1060.
51. Agency for Healthcare Research and Quality. HCUPnet, healthcare cost and utilization. Available at: http://hcup.ahrq.gov/HCUPnet.asp. Accessed January 14, 2003, 2004.
52. Leibson CL, Hu T, Brown RD, Hass SL, O'Fallon WM, Whisnant JP. Utilization of acute care services in the year before and after first stroke: a population-based study. Neurology. 1996;46:861-869.
53. Holloway RG, Witter DM Jr, Lawton KB, Lipscomb J, Samsa G. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology. 1996;46:854-860.
54. Matchar DB, Samsa GP. Secondary and Tertiary Prevention of Stroke: Patient Outcomes Research Team (PORT) Final Report-Phase 1. Rockville, Md: Agency for Healthcare Research and Quality; 2000. AHRQ publication 00-N0001.
55. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford M. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
56. Gullov AL, Koefoed BG, Petersen P. Bleedingduring warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study: Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med. 1999;159:1322-1328.
57. Wehinger C, Stollberger C, Langer T, Schneider B, Finsterer J. Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke. 2001;32:2246-2252.
58. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348:423-428.
59. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White R. The risk for and severity of bleeding complications in elderly patients treated with warfarin: the National Consortium of Anticoagulation Clinics. Ann Intern Med. 1996;124:970-979.
60. Casais P, Luceros AS, Meschengieser S, Fondevila C, Santarelli MT, Lazzari MA. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol. 2000;63:192-196.
61. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995;70:725-733.
62. Gorter JW; European Atrial Fibrillation Trial (EAFT) Study Groups. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors: Stroke Prevention In Reversible Ischemia Trial (SPIRIT). Neurology. 1999;53:1319-1327.
63. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med. 1991;229:351-355.
64. US Department of Labor Bureau of Labor Statistics. Consumer Price Index: table containing history of CPI-U US: all items indexes and annual percent changes from 1913 to present. Available at: http://www.bls.gov/cpi/. Accessed February 26, 2004.
65. Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med. 2000;109:481-488.
66. SMLTREE [computer program]. Version SML3. New York, NY: Pratt Medical Group; 1995.
67. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med. 1998;13:716-717.
68. Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34:2060-2065.
69. Lee SH, Bae HJ, Kwon SJ, et al. Cerebral microbleeds are regionally associated with intracerebral hemorrhage. Neurology. 2004;62:72-76.
70. Beyth RJ, Milligan PE, Gage BF. Risk factors for bleeding in patients taking coumarins. Curr Hematol Rep. 2002;1:41-49.
71. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage and the role of warfarin in patients with atrial fibrillation who are prone to fall. Am J Med. In press.
72. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA. 1999;282:737-743.
73. Johnston JA, Eckman MH. Use of regression modeling to simulate patient-specific decision analysis for patients with nonvalvular atrial fibrillation. Med Decis Making. 2003;23:361-368.
74. AstraZeneca Exanta liver toxicity outweighs benefit, cmte. says. Available at: http://www.fdaadvisorycommittee.com/FDC/AdvisoryCommittee/ Committees/Cardiovascular+and+Renal+Drugs/091004_Exanta/091004_ExantaR.htm. Accessed January 14, 2005.
75. Waterman A, Milligan P, Bayer L, Banet G, Gatchel S, Gage B. Effect on warfarin nonadherence on control of the international normalized ratio. Am J Health Syst Pharm. 2004;61:1258-1264.